If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
== Early career == Levé was born in Neuilly-sur-Seine on 1 January 1965. He was self-taught as an artist and studied business at the elite ESSEC Business School. He began painting in 1991. Levé made abstract paintings but abandoned the field (claiming to have burned most of his paintings) and took up color photography upon his return from an influential two-month trip to India in 1995.
=== Downworlders === Hypatia Vex — a warlock who owns the Hell Ruelle. Malcolm Fade — High Warlock of London, succeeding Ragnor Fell. Magnus Bane — a powerful warlock, and old friend of Will Herondale's and Tessa Gray's.
I.E.M. (album) Inborn error of metabolism In-ear monitors, devices used by musicians, audio engineers and audiophiles to listen to music Incredible Expanding Mindfuck (Music) Information Engineering Methodology Institute of Electronic Music and Acoustics (Institut für Elektronische Musik und Akustik), part of the University of Music and Performing Arts, Graz Institute of Engineering and Management Integrated Enterprise Modeling Institute of Engineering in Medicine, part of the University of California, San Diego Institute for Experimental Mathematics, a central scientific facility of the University of Duisburg-Essen Intel Extreme Masters, a series of international esports tournaments International emergency medicine Internet Explorer Mobile Ion evaporation model, a model explaining electrospray ionization in mass spectrometry Iowa Electronic Markets Internal Energy Market, of the European Union
Sources: en.wikipedia.org
== Society and culture == As of 2018, there is a lack of compelling evidence to conclude superiority of insulin aspart over human insulin in type 2 diabetes. It is thus unclear why the shifting of people from human insulin to insulin aspart has occurred. In type 1 diabetes it appears to result in slightly better blood sugar control.
== The role of Russian peacekeepers == On 12 August 2008, Life.ru reported that several Russian peacekeepers were buried in Vladikavkaz. Among them was 32-year-old lieutenant colonel Oleg Golovanov, native of Tskhinvali, who fought against the Georgian army for several hours. Moskovskij Komsomolets published an article where one senior officer of the mortar battery is documented as saying that Oleg Golovanov was the commander of an artillery reconnaissance platoon and was sitting on the roof of the peacekeepers' base and corrected fire. Golovanov was wounded. He died on Friday (8 August 2008). According to MK, Oleg Golovanov was buried in Tskhinvali on 11 August 2008. REGNUM News Agency published the list of killed Russian peacekeepers on 12 August 2008, where lieutenant colonel Oleg Golovanov is included. In the August 2008 issue of Spetsnaz Rossii Oleg Golovanov was described as lieutenant colonel who commanded one group of Russian peacekeepers resisting the Georgian advance. This group fought against the Georgian army for several hours. In November 2008, OsRadio reported that on 7 August Lieutenant Oleg Galavanov was following orders to detect the targets and adjust artillery fire. Galavanov was adjusting fire aimed at advancing Georgian army during the night until the Georgians located his position and he was wounded. He was awarded the title of Hero of the Russian Federation. In February 2009, Galavanov's mother said in an interview that her 32-year old son worked in the intelligence service in the South Ossetian Ministry of Defense and had the rank of lieutenant.
== Heparan sulfate analogues == Several Heparan sulfate analogues (also known as ReGeneraTing Agents, RGTA) have been developed from a poly glucose backbone. One named OTR4120 is a 85KD biopolymer and used for topical or ophthalmological application and marketed under the name CACIPLIQ20 or CACICOL20, respectively. Heparan sulfate analogues will occupy the free heparan sulfate binding sites on ECM macromolecules like collagen, fibronectin and laminin that become available following heparan sulfate degradation. In many characteristics heparan sulfate analogues are similar to the natural heparan sulfate. The most important difference is their resistance to enzymatic degradation. The resistance of RGTA is caused by the coupling of the subunits internal bond of the molecules. The β1-4 oxygen-linked binding of the subunits of heparan sulfate is prone to enzymatic cleavage whereas the α1-6 carbon-carbon binding of the subunits of RGTA are resistant to cleavage by all known mammalian glycanases and heparanases. This way RGTA can recreate a scaffold with the ECM proteins and will reposition GFs back into the matrix where they can re-unfold their natural action in wound repair. This way heparan sulfate analogues may contribute to chronic wound healing as will be discussed later on.
Sources: en.wikipedia.org
==== Dehydrogenases: equivalents to complexes I and II ==== Bacteria can use several different electron donors. When organic matter is the electron source, the donor may be NADH or succinate, in which case electrons enter the electron transport chain via NADH dehydrogenase (similar to Complex I in mitochondria) or succinate dehydrogenase (similar to Complex II). Other dehydrogenases may be used to process different energy sources: formate dehydrogenase, lactate dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase, H2 dehydrogenase (hydrogenase), electron transport chain. Some dehydrogenases are also proton pumps, while others funnel electrons into the quinone pool. Most dehydrogenases show induced expression in the bacterial cell in response to metabolic needs triggered by the environment in which the cells grow. In the case of lactate dehydrogenase in E. coli, the enzyme is used aerobically and in combination with other dehydrogenases. It is inducible and is expressed when the concentration of DL-lactate in the cell is high.
==== Land ==== The Peak Tram, Hong Kong's first public transport system, has provided funicular rail transport between Central and Victoria Peak since 1888. The Central and Western District has an extensive system of escalators and moving pavements, which, together with the Mid-Levels escalator system, is the world's longest outdoor covered escalator system. Hong Kong Tramways' tram network covers a portion of Hong Kong Island, covering from Kennedy Town to Shau Kei Wan, with a branch to Happy Valley. It operates 6 routes and has had a ridership of 42,558 in 2022. It began servicing Hong Kong since 1904. Hong Kong Tramways currently holds the Guinness World Record as the "Largest double-decker tram fleet in service", certified on 30 July 2021, with a fleet of 165 double-decker trams. The fleet of trams was mostly built by Hong Kong Tramways.
Avanti West Coast operates an hourly service between Manchester Piccadilly and London Euston, via Crewe Northern Trains operates regular local services to Manchester Piccadilly, Stockport, Manchester Airport, Alderley Edge and Crewe Transport for Wales operates an hourly service to Cardiff Central, via Crewe, Shrewsbury and Hereford; alternate services continue on to Carmarthen, Fishguard Harbour, Milford Haven or Pembroke Dock.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.